Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.

@article{Djukanovi2004EffectsOT,
  title={Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.},
  author={Ratko Djukanovi{\'c} and Susan J Wilson and Monica Kraft and Nizar N. Jarjour and Mark D Steel and Kian Fan Chung and Weibin Bao and Angel Fowler-Taylor and John Matthews and William W. Busse and Stephen T Holgate and John V. Fahy},
  journal={American journal of respiratory and critical care medicine},
  year={2004},
  volume={170 6},
  pages={
          583-93
        }
}
IgE plays an important role in allergic asthma. We hypothesized that reducing IgE in the airway mucosa would reduce airway inflammation. Forty-five patients with mild to moderate persistent asthma with sputum eosinophilia of 2% or more were treated with humanized monoclonal antibody against IgE (omalizumab) (n = 22) or placebo (n = 23) for 16 weeks. Outcomes included inflammatory cells in induced sputum and bronchial biopsies, and methacholine responsiveness. Treatment with omalizumab resulted… Expand
The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation.
TLDR
The anti-inflammatory effects of omalizumab at different sites of allergic inflammation and the clinical benefits of anti-IgE therapy in patients with allergic asthma and allergic rhinitis emphasize the fundamental importance of IgE in allergic inflammation. Expand
Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab.
  • D. Nowak
  • Medicine
  • Respiratory medicine
  • 2006
TLDR
Patients with uncontrolled severe persistent allergic asthma are a challenging and difficult-to-treat population for whom omalizumab might represent an important new treatment option and may provide a means to address comorbid allergic disease in patients with asthma. Expand
Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma.
TLDR
These findings provide further evidence that omalizumab has additional anti-inflammatory activity demonstrated by induction of eosinophil apoptosis and downregulation of the inflammatory cytokines IL-2 and IL-13. Expand
The effect of omalizumab on eosinophilic inflammation of the respiratory tract in patients with allergic asthma.
TLDR
The paper discusses the efficacy of omalizumab in reducing eosinophil number in peripheral blood and in the airways of asthmatic patients based on basic, clinical, observational studies and case reports. Expand
Effects of omalizumab on markers of inflammation in patients with allergic asthma
TLDR
The anti‐inflammatory effects of omalizumab may explain the reductions in asthma exacerbations and symptoms seen in clinical trials in patients with moderate‐to‐severe or severe, persistent, inadequately controlled allergic asthma. Expand
Treatment with Anti-IgE Monoclonal Antibody and Free IgE
TLDR
Treatment with omalizumab significantly reduces asthma symptoms, frequency of reliever use, and severe asthma exacerbations while improving pulmonary function in patients with severe allergic asthma who experience inadequate control with high doses of inhaled corticosteroids and other controllers. Expand
Anti‐immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti‐inflammatory activity and clinical efficacy
TLDR
Systemic anti‐IgE therapy with omalizumab has been shown to improve symptoms, quality of life and disease control in patients with concomitant asthma and persistent AR and to emphasize the fundamental importance of IgE in the pathogenesis of allergic diseases. Expand
Omalizumab in the management of patients with allergic (IgE-mediated) asthma
TLDR
In clinical trials in adults and adolescents, omalizumab reduced asthma exacerbations, severe asthma exacerbation, inhaled corticosteroid requirements, and emergency visits, as well as significantly improving asthma-related quality of life, morning peak expiratory flow and asthma symptom scores in patients with severe allergic (IgE-mediated) asthma. Expand
Association of upper and lower airway eosinophilic inflammation with response to omalizumab in patients with severe asthma
TLDR
The phenotype associated with response to omalizumab, leading to improvement in asthma symptoms, comprises upper airway eosinophilia and high FeNO levels, suggesting heterogeneity among people with severe asthma. Expand
Omalizumab: an anti-immunoglobulin E antibody for the treatment of allergic respiratory diseases
TLDR
In patients with poorly controlled asthma, omalizumab reduced the asthma exacerbation and emergency visit rate, along with improving the quality of life and the improvement in asthma control was associated with a reduction of inhaled and oral corticosteroids. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 51 REFERENCES
Immunological and Clinical Changes in Allergic Asthmatics following Treatment with Omalizumab
TLDR
It is suggested that omalizumab has potential as a novel treatment for allergic asthma and circulating levels of inflammatory mediators and clinical symptoms in patients with moderate to severe allergic asthma decreased. Expand
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
TLDR
The addition of omalizumab to standard asthma therapy reduces asthma exacerbations and decreases inhaled corticosteroid and rescue medication use. Expand
The effect of omalizumab on nasal allergic inflammation.
TLDR
The clinical benefit of treatment with omalizumab is associated with an anti-inflammatory effect on cellular markers in blood and nasal tissue. Expand
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.
TLDR
Results indicate that omalizumab therapy safely improves asthma control in allergic asthmatics who remain symptomatic despite regular use of inhaled corticosteroids and simultaneous reduction in Corticosteroid requirement. Expand
Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response.
TLDR
The inhibitory effects of rhuMAb-E25 on allergen-induced EAR suggest that it may be an effective, novel antiallergic treatment for asthma. Expand
Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response
TLDR
A single dose of monoclonal antibody to IL-5 decreased blood eosinophils for up to 16 weeks and sputum eosInophils at 4 weeks, which has considerable therapeutic potential for asthma and allergy, however, the findings question the role of eos inophils in mediating the late asthmatic response and causing airway hyper-responsiveness. Expand
Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
TLDR
Omalizumab has been reported to be safe and effective in improving asthma control and reducing the requirement for oral and inhaled corticosteroids, and cause a down-regulation of FcepsilonRI receptors on basophils. Expand
Analysis of induced sputum to examine the effects of prednisone on airway inflammation in asthmatic subjects.
TLDR
Analysis of induced sputum is a useful noninvasive method for studying the effects of asthma therapy on airway eosinophilic inflammation and prednisone treatment was not associated with any significant change in the concentrations of albumin or mucin-like glycoprotein. Expand
Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.
TLDR
A recombinant humanized monoclonal antibody directed against IgE has potential as a treatment for subjects with moderate or severe allergic asthma and was well tolerated. Expand
Treatment of allergic asthma with monoclonal anti-IgE antibody.
TLDR
The efficacy of rhuMAb-E25 as a treatment for moderate-to-severe allergic asthma, a recombinant humanized monoclonal antibody that forms complexes with free IgE and blocks its interaction with mast cells and basophils is studied. Expand
...
1
2
3
4
5
...